SCHEMBL29778409

SCHEMBL29778409

COCCNC(=O)c1cccc(Cn2ccc3cc(-c4ccnn4C)ccc3c2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 1/20 0.43
MAP1LC3A Q9H492 1/20 0.43
ROCK2 O75116 2/20 0.43
ROCK1 Q13464 1/20 0.43
BRD4 O60885 3/20 0.41
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
CTSV O60911 1/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
CD274 Q9NZQ7 1/20 0.39
P2RX7 Q99572 1/20 0.39
TP53 P04637 2/20 0.39
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29135937 1.00 MAP1LC3B (0.43) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4
SCHEMBL24616927 0.89 KDM4E (0.44) MAP1LC3BMAP1LC3AROCK2ROCK1KDM4E
SCHEMBL31232266 0.89 KDM4E (0.44) MAP1LC3BMAP1LC3AROCK2ROCK1KDM4E
SCHEMBL24616956 0.88 MAP1LC3B (0.47) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4
SCHEMBL29778481 0.87 MAP1LC3B (0.43) MAP1LC3BMAP1LC3AROCK2ROCK1CTSV
SCHEMBL24616895 0.85 MAP1LC3B (0.44) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4
SCHEMBL29778567 0.85 MAP1LC3B (0.44) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4
SCHEMBL24616902 0.85 MAP1LC3B (0.43) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4
SCHEMBL29778371 0.85 MAP1LC3B (0.43) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4
SCHEMBL24616892 0.85 MAP1LC3B (0.47) MAP1LC3BMAP1LC3AROCK2ROCK1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US claimed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP claimed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO claimed
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF Genosco Inc. 2024-11-14 US disclosed
EP-4274825-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2023-11-15 EP disclosed
WO-2022150381-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374582-A1 SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF ROCK2, ROCK1, MYLK3 MAP1LC3B 122/4885MAP1LC3A 108/4885ROCK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.